Gastric Cancer Market - Infographics - AMR
The gastric cancer market was valued at $2.1 billion in 2021, and is estimated to reach $10.7 billion by 2031, growing at a CAGR of 17.9% from 2022 to 2031.
Based on region, the Asia-Pacific market registered the highest gastric cancer market share in 2021 and is projected to maintain its position during the forecast period.— Allied Market Research
WILMINGTON, DELAWARE , UNITED STATES, July 24, 2024 /
EINPresswire.com/ -- According to a new report published by Allied Market Research, titled, “
Gastric Cancer Market," The
gastric cancer market size was valued at $2.1 billion in 2021, and is estimated to reach $10.7 billion by 2031, growing at a CAGR of 17.9% from 2022 to 2031, fueled by innovative treatment advancements and strategic industry initiatives. A newly published report offers an in-depth analysis of emerging therapies and the strategic dynamics reshaping the future of gastric cancer care.
As gastric cancer remains one of the leading causes of cancer-related mortality worldwide, significant efforts in research and development have led to groundbreaking therapeutic advancements. New targeted therapies, immunotherapies, and personalized medicine approaches are transforming patient outcomes and setting new standards in gastric cancer treatment.
By treatment type, the chemotherapy segment captured nearly half of the global gastric cancer market revenue and is expected to maintain its dominance by 2031. Conversely, the targeted therapy segment is projected to achieve the fastest compound annual growth rate (CAGR) of 19.2% during the forecast period. The report also examines the immunotherapy, radiation therapy, and surgery segments.
𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭
https://www.alliedmarketresearch.com/request-sample/A74458
By drug class outlook, the PD-1/PD-L1 inhibitors segment is forecasted to exhibit the fastest CAGR of 18.7% throughout the forecast period. The report also analyzes the HER2 antagonists, VEGFR2 antagonists, and other segments.
By distribution channel, the specialty and retail pharmacies segment accounted for nearly three-fifths of the global gastric cancer market revenue and is anticipated to retain its leading position by 2031. This segment is also expected to register the fastest CAGR of 18.5% over the forecast period. Additionally, the report evaluates the hospital pharmacies and other segments.
𝐊𝐞𝐲 𝐅𝐢𝐧𝐝𝐢𝐧𝐠𝐬 𝐨𝐟 𝐭𝐡𝐞 𝐒𝐭𝐮𝐝𝐲
Based on disease type, the adenocarcinoma sub-segment emerged as the global leader in 2021 and is anticipated to be the fastest growing during the gastric cancer market forecast period
Based on treatment type, the chemotherapy sub-segment emerged as the global leader in 2021 and the targeted therapy sub-segment is predicted to show the fastest growth in the upcoming years
Based on drug class outlook, the PD-1/PD-L1 inhibitors sub-segment emerged as the global leader in 2021 and is predicted to show the fastest growth in the upcoming years
Based on route of administration, the oral sub-segment emerged as the global leader in 2021 and is predicted to show the fastest growth in the upcoming years
Based on distribution channel, the specialty & retail pharmacies sub-segment emerged as the global leader in 2021 and is predicted to show the fastest growth in the upcoming years
Based on region, the Asia-Pacific market registered the highest gastric cancer market share in 2021 and is projected to maintain its position during the forecast period.
𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 𝐅𝐨𝐫 𝐒𝐭𝐚𝐤𝐞𝐡𝐨𝐥𝐝𝐞𝐫𝐬
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gastric cancer market analysis from 2021 to 2031 to identify the prevailing gastric cancer market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the gastric cancer market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global gastric cancer market trends, key players, market segments, application areas, and market growth strategies.
𝐊𝐞𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬
Samsung Bioepis
Celltrion Healthcare Co., Ltd.
Eli Lilly & Company
Merck & Co., Inc.
Bristol Myers Squibb Company
Mylan N.V.
Novartis AG
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.
F. Hoffmann La Roche Ltd.
𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐢𝐧 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐃𝐨𝐦𝐚𝐢𝐧
𝐓𝐮𝐦𝐨𝐫 𝐀𝐛𝐥𝐚𝐭𝐢𝐨𝐧 𝐦𝐚𝐫𝐤𝐞𝐭
https://www.alliedmarketresearch.com/tumor-ablation-market-A17208
𝐍𝐢𝐜𝐨𝐭𝐢𝐧𝐞 𝐑𝐞𝐩𝐥𝐚𝐜𝐞𝐦𝐞𝐧𝐭 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭
https://www.alliedmarketresearch.com/nicotine-replacement-therapy-market-A31526David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter